OM1, a health technology company, announced an $85 million financing led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital; with participation from existing investors, including General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest.

OM1 partners with providers, medical societies, payers, and manufacturers to harness real-world data for advancing medical research, evaluating health outcomes, obtaining regulatory approvals, and personalizing treatment in chronic disease areas, such as dermatology, rheumatology, cardiology, gastroenterology, respiratory, neurosciences, and behavioral health.